Elekta (OTCMKTS:EKTAY) Shares Climb 5.5% – Still a Buy?

Elekta AB (OTCMKTS:EKTAY)’s stock price shot up 5.5% on Monday. The company traded as high as $5.57 and last traded at $5.57. Approximately 100 shares changed hands during trading, a decline of 97% from the average daily volume of 2,869 shares. The stock had previously closed at $5.28.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, Elekta currently has an average rating of “Hold”.

Elekta Trading Up 3.0%

The company has a 50 day simple moving average of $5.38 and a 200 day simple moving average of $5.49. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.62 and a current ratio of 0.86. The company has a market capitalization of $2.05 billion, a PE ratio of -46.41 and a beta of 1.03.

Elekta (OTCMKTS:EKTAY) last announced its earnings results on Thursday, August 27th. The company reported $0.07 EPS for the quarter. The business had revenue of $372.30 million during the quarter. Elekta had a positive return on equity of 13.47% and a negative net margin of 2.38%. Analysts anticipate that Elekta AB will post 0.43 earnings per share for the current year.

Elekta Company Profile

Elekta AB is a Sweden-based medical technology company that develops and supplies equipment, software and related services for radiation oncology and neurosurgery. Its technologies are used by hospitals and cancer treatment centers to plan and deliver precision radiation treatments for patients with cancer and neurological disorders.

The company’s portfolio includes linear accelerators, stereotactic radiosurgery systems, brachytherapy solutions, treatment-planning and oncology information software, and magnetic resonance-guided radiation therapy technology.